Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion, Kaiser Permanente to Collaborate on Ovarian Cancer Best Practices

NEW YORK (GenomeWeb) – Vermillion today announced it will collaborate with Kaiser Permanente's Southern California Permanente Medical Group to create best practice guidelines to improve the diagnosis and treatment of ovarian cancer.

The program will begin with a benchmarking study to identify opportunities for early intervention. Through the use of electronic medical records, the study will track patient experiences, from the initial presentation of disease through to patient outcomes following diagnosis and treatment, including surgical intervention.

Many cases of ovarian cancer are detected at a late stage and have poor five-year survival prospects, Vermillion said in a statement, also noting that existing treatment options can improve survival by as much as 30 percent.

Vermillion said that the study could open the door for further collaboration to identify the role of Vermillion's OVA1 and OVA2 diagnostic tests in informing ovarian cancer treatment decisions.

In March, Vermillion made a 510(k) submission to the US Food and Drug Administration for clearance of the second-generation OVA2 ovarian cancer test.